Form 4 for HUMA Humacyte, Inc.
Accepted 2022-09-19 00:00:00 ET · period of report 2022-09-15 · accession 0001818382-22-000160 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-09-19 | 2022-09-15 | HUMA | Dougan Brady W | Dir, 10% | S - Sale | $4.00 | -1.52M | 18.93M | -7% | -$6.09M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-15 | S | D | 1,522,500 | $4.00 | 18,930,004 | I By Ayabudge LLC | — | — | (F1) The sale was made by Ayabudge LLC, an entity controlled by Brady W Dougan, in a block trade. The purchaser is an existing investor of the Issuer, who had previously participated in the Issuer's PIPE financing transaction, and was interested in increasing its ownership of the Humacyte, Inc. The transaction enabled Mr. Dougan to pay down leverage while providing a mechanism for the purchaser to acquire a large block of shares at a time that Humacyte, Inc. was not conducting a financing and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. |